A research team led by scientists from the Karolinska Institute and Danderyd Hospital in Sweden report that high levels of mucosal antibodies in the airways reduce the risk of being infected by omicron. However, many people do not receive detectable antibodies in the airways despite three doses of the SARS-CoV-2 vaccine, add the researchers.
Their study “Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection” is published in the New England Journal of Medicine.
